Expert Consensus Document on the Use of Antiplatelet Agents: The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology

European Heart Journal

Volumn 25, Issue 2, 2004, Pages 166-181

  Patrono, Carlo ^a,b   Bachmann, Fedor ^a   Baigent, Colin ^a   Bode, Christopher ^a   De Caterina, Raffaele ^a   Charbonnier, Bernard ^a   Fitzgerald, Desmond ^a   Hirsh, Jack ^a   Husted, Steen ^a   Kvasnicka, Jan ^a   Montalescot, Gilles ^a   García Rodríguez, Luis Alberto ^a   Verheust, Freek ^a   Vermylen, Jozef ^a   Wallentin, Lars ^a  

^a II Facoltà di Med e Chir ^*

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLURBIPROFEN; IFETROBAN; INDOBUFEN; LOTRAFIBAN; NONSTEROID ANTIINFLAMMATORY AGENT; ORBOFIBAN; PICOTAMIDE; PROTON PUMP INHIBITOR; SIBRAFIBAN; SULFINPYRAZONE; SULOTROBAN; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TICLOPIDINE; TIROFIBAN; TRIFLUSAL; VAPIPROST; XEMILOFIBAN;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HUMAN; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 9144270451     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.10.013     Document Type: Conference Paper

References (75)

1. Patrono C, Coller B, Daten JE et al. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
2. Antithrombotic Trialists' Collaboration. Prevention of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. BMJ 2002;324:71-86.
3. Kroll MH, Sullivan R. Mechanisms of platelet activation. In: Loscalzo J, Schafer Al, editors. Thrombosis and Hemorrhage. Baltimore: William & Wilkins; 1998, p. 261-91.
4. Patrono C. Pharmacology of antiplatelet agents. In: Loscalzo J, Schafer AI, editors. Thrombosis and Hemorrhage. Baltimore: William & Wilkins; 1998, p. 1181-92.
5. Kaushansky K. Regulation of megakaryopoiesis. In: Loscalzo J, Schafer AI, editors. Thrombosis and Hemorrhage. Baltimore: William Wilkins; 1998, p. 173-93.
6. Rocca B, Secchiero P, Ciabattoni G et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634-9.
7. Lindemann S, Tolley ND, Dixon DA et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol 2001;154:485-90.
8. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108:7-13.
9. FitzGerald GA, Austin S, Egan K et al. Cyclooxygenase products and atherothrombosis. Ann Med 2000;32(Suppl 1):21-6.
10. Marcus AJ, Broekman MJ, Drosopoulos JH et al. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases. Ital Heart J 2001;2:824-30.
11. Cicmil M, Thomas JM, Leduc M et al. Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood 2002;99:137-44.
12. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
13. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and ·2. J Biol Chem 1996;271:33157-60.
14. Cipollone F, Patrignani P, Greco A et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 1997;96:1109-16.
15. Taylor DW, Barnett HJ, Haynes RB et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 1999;355:1295-305.
16. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-72.
17. Garcia Rodríguez LA, Cattaruzzi C, Troncon MG et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998;158:33-9.
18. Savi P, Pereillo JM, Uzabiaga MF et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6.
19. Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-7.
20. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
21. CURE Steering Committee. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
22. Bertrand ME, Rupprecht H-J, Urban P et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
23. Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
24. García Rodríguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382-7.
25. Ray WA, Stein CM, Hall K et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.
26. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
27. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
28. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-6.
29. Peter K, Schwarz M, Ylanne J et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998;92:3240-9.
30. Cox D, Smith R, Quinn M et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000;36:1514-9.
31. Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemostas 1998;79:691-705.
32. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997;17:2309-15.
33. Cipollone F, Ciabattoni G, Patrignani P et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000;102:1007-13.
34. 12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001;12:197-209.
35. Scrutinio D, Cimminiello C, Marubini E et al. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001;37:1259-65.
36. Juul-Möller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-5.
37. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
38. García Rodriguez LA, Hernandez-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combination of these agents. Arthritis Res 2001;3:98-101.
39. Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomized controlled trial. BMJ 2000;321:13-7.
40. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001;357:89-95.
41. Hayden M, Pignone M, Phillips C et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
42. Sanmuganathan PS, Ghahramani P, Jackson PR et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart 2001;85:265-71.
43. Nowak J, Murray JJ, Oates JA et al. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987;76:6-14.
44. Davi G, Catalano I, Averna M et al. Thromboxane biosynthesis and platelet function in type-II diabetes mellitus. N Engl J Med 1990;322:1769-74.
45. Davi G, Notarbartolo A, Catalano I et al. Increased thromboxane biosynthesis in type Ila hypercholesterolemia. Circulation 1992;85:1792-8.
46. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001;358:1533-8.
47. Cannon CP, Turpie AGG. Unstable angina and non-ST-elevation myocardial infarction. Circulation 2003;107:2640-5.
48. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
49. Albers GW, Amarenco P, Easton JD et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119:300S-20S.
50. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
51. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189-98.
52. The Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002;105:316-21.
53. Stafford RS. Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000;101:1097-101.
54. MRC/BHF Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of anti-oxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease: early safety and efficacy experience. Eur Heart J 1999;20:725-41.
55. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2002;25(Suppl 1):S78-9.
56. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 1997;14(Suppl 5):S1-S85.
57. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-52.
58. Jubilerer SJ. Hemostatic abnormalities in renal disease. Am J Kidney Dis 1985;5:219-25.
59. Buring JE, Hennekens CH, for the Women's Health Study Research Group A. The Women's Health Study: summary of the study design. J Myocard Isch 1992;4:27-9.
60. De Schryver ELLM, on behalf of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group. Design of ESPRIT: An International Randomized Trial for Secondary Prevention after Non-Disabling Cerebral Ischaemia of Arterial Origin. Cerebravasc Dis 2000;10:147-50.
61. Second Chinese Cardiac Study (CCS-2) Collaborative Group. Rationale, design and organisation of the Second Chinese Cardiac Study (CCS-2): a randomised trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk 2000;7:435-41.
62. Popma JJ, Ohman EM, Weitz J et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001;119:321S-36S.
63. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
64. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
65. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Inverstigators. Circulation 1998;98:734-41.
66. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
67. Montalescot G, Barrasan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
68. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
69. Stein PD, Dalen JE, Goldman S et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 2001;119:278S-82S.
70. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 2001;119:283S-99S.
71. TDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA 1992;268:1292-300.
72. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
73. Salem DN, Daudelin DH, Levine HJ et al. Antithrombotic therapy in valvular heart disease. Chest 2001;119:207S-19S.
74. Stein PD, Alpert JS, Bussey HJ et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119:220S-7S.
75. Guyatt G, Schunëmann H, Cook D et al. Grades of recommendation for antithrombotic agents. Chest 2001;119:3S-7S.